Indications: Solid tumors / AMD

PMC-403 is a monoclonal antibody that targets the human Tie2 that regulate the angiogenesis and vessel maturation in endothelial cells.

Mechanism of action / Target

PMC-403 binds to TIE2 expressing endothelial cells that normalize VEGF-induced tumor vessel leakage in the tumor microenvironment (TME).


PMC-403 was tested in various vessel-related disease such as age-related macular degeneration(AMD), diabetic retinopathy, and cancer. In these models, significant vessel normalizing effect was found which suggest versatile use in wide indications. GLP-toxicity study needed for the IND application will be completed in the near future.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.